Patents Represented by Attorney Ronald C. Lundquist
  • Patent number: 6083708
    Abstract: Compositions are disclosed, comprising dendrimers to which a first polypeptide is controllably coupled. Such polypeptide-dendrimer compositions are effective for controllably coupling a second polypeptide to the dendrimer. The first and second polypeptides have separate and distinct defined biological activities, for example, two antibodies with first and second binding specificities or an antibody and an enzymatic label. Such compositions are useful as indicators in specific binding assays, e.g., immunoassays. Methods for sequentially coupling two different polypeptides to a dendrimer to form compositions of the invention also are disclosed.
    Type: Grant
    Filed: August 11, 1995
    Date of Patent: July 4, 2000
    Assignee: Dade Behring Inc.
    Inventors: Pratap Singh, Spencer Lin, Fred Moll, III
  • Patent number: 5898005
    Abstract: Methods are provided for conducting specific binding assays to determine the concentration or presence of at least one analyte in a sample. Dendrimer-reagent preparations with particular analyte specificities are mixed in solution with a sample to form dendrimer-reagent-sample complexes. The complexes are then immobilized on a solid phase. Immobilization is facilitated by coupling specific binding assay reagents such as polypeptide receptors or analytes with water soluble polymers. Such water soluble polymers, for example star polymers such as dendrimers, provide production advantages of lot-to-lot uniformity and homogeneity, and can enhance sensitivity due to low non-specific binding to the solid phase.
    Type: Grant
    Filed: April 13, 1994
    Date of Patent: April 27, 1999
    Assignee: Dade Behring Inc.
    Inventors: Pratap Singh, Fred Moll, III, Peter Cronin, Spencer H. Lin, Charles Ferzli, Kent Koski, Richard Saul
  • Patent number: 5866402
    Abstract: Chimeric proteins containing sequences from MCP and DAF and further containing peptide sequences capable of binding glycosaminoglycans. Nucleotide sequences encoding the chimeric proteins, expression vectors containing the nucleotide sequences, as well as transformed host cells capable of producing the chimeric proteins are claimed.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: February 2, 1999
    Assignee: Chiron Corporation
    Inventors: Michael A. Innis, Isabel Zaror, Abla A. Creasey
  • Patent number: 5861319
    Abstract: Methods and compositions are provided for specific binding assays in which specific binding reagents are immobilized on a solid phase. Immobilization is facilitated by covalently coupling specific binding assay reagents such as polypeptide receptors or analytes with water soluble polymers. Such water soluble polymers, for example star polymers such as dendrimers, provide production advantages of lot-to-lot uniformity and homogeneity, and can enhance sensitivity due to low non-specific binding to the solid phase.
    Type: Grant
    Filed: October 28, 1994
    Date of Patent: January 19, 1999
    Assignee: Dade Behring Inc.
    Inventors: Spencer H. Lin, Kwok Sum Yu, Pratap Singh, Steven E. Diamond
  • Patent number: 5824839
    Abstract: Disclosed are methods that achieve i) site-directed delivery, ii) in situ amplification, and iii) sustained expression of an exogenous gene product within renal glomeruli. An exogenous gene, E. coli .beta.-galactosidase, was introduced into cultured rat mesangial cells using a replication-defective retrovirus, and stable infectants were administered to a rat kidney via the renal artery. In the injected kidney, the engineered, cultured mesangial cells populated 40% of glomeruli site-specifically. The gene product was detected throughout a 14-week period of observation. In an alternative method, engineered, cultured mesangial cells were injected into a kidney subjected to an antibody that induces mesangiolysis followed by mesangial regeneration. Under these conditions, expression of .beta.-galactosidase was dramatically amplified in situ and high level expression continued for at least 8 weeks.
    Type: Grant
    Filed: April 9, 1997
    Date of Patent: October 20, 1998
    Assignee: The Jikei University School of Medicine
    Inventor: Masanori Kitamura